Traws Pharma (TRAW) Total Liabilities (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Total Liabilities of $13.5 million for Q1 2026, up 3.09% year-over-year from $13.1 million in Q1 2025, and up 19.75% quarter-over-quarter from $11.2 million in Q4 2025.
Traws Pharma (TRAW) Total Liabilities (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Total Liabilities for 15 consecutive years, with $13.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 3.09% year-over-year to $13.5 million; the TTM figure through Mar 2026 stood at $13.5 million (up 3.09% YoY), while the FY2025 annual figure was $11.2 million, down 80.13% from the prior year.
- Total Liabilities grew to $13.5 million in Q1 2026 per TRAW's latest filing, from $11.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $56.6 million in Q4 2024 and bottomed at $7.4 million in Q2 2025.
- Historically, Total Liabilities has averaged $13.8 million across 5 years, with a median of $11.6 million in 2023.
- Annual changes were most pronounced in 2024 — Total Liabilities soared 371.17% — and 2025, when it slumped 80.13%.
- Traws Pharma's Total Liabilities stood at $11.1 million in 2022, then gained by 8.57% to $12.0 million in 2023, then soared by 371.17% to $56.6 million in 2024, then plunged by 80.13% to $11.2 million in 2025, then increased by 19.75% to $13.5 million in 2026.
- Business Quant data shows TRAW's Total Liabilities at $13.5 million in Q1 2026, $11.2 million in Q4 2025, and $7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 10.03 Bn |
| 10 | Traws Pharma | 5.54 Mn | 519,253.28 | - | 9.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.47 Mn |
| Dec 31, 2025 | 11.25 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Jun 30, 2025 | 7.36 Mn |
| Mar 31, 2025 | 13.06 Mn |
| Dec 31, 2024 | 56.59 Mn |
| Sep 30, 2024 | 10.97 Mn |
| Jun 30, 2024 | 12.59 Mn |
| Mar 31, 2024 | 12.16 Mn |
| Dec 31, 2023 | 12.01 Mn |
| Sep 30, 2023 | 12.52 Mn |
| Jun 30, 2023 | 11.57 Mn |
| Mar 31, 2023 | 12.19 Mn |
| Dec 31, 2022 | 11.06 Mn |
| Sep 30, 2022 | 10.41 Mn |
| Jun 30, 2022 | 9.59 Mn |
| Mar 31, 2022 | 9.14 Mn |
| Dec 31, 2021 | 9.36 Mn |
| Sep 30, 2021 | 10.32 Mn |
| Jun 30, 2021 | 11.39 Mn |